Mhairi Copland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6058870/publications.pdf

Version: 2024-02-01

54 papers	2,760 citations	279487 23 h-index	182168 51 g-index
58 all docs	58 docs citations	58 times ranked	3658 citing authors

#	Article	IF	Citations
1	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 2006, 107, 4532-4539.	0.6	590
2	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature, 2016, 534, 341-346.	13.7	204
3	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 2020, 20, 158-173.	12.8	181
4	EZH2 in normal and malignant hematopoiesis. Leukemia, 2014, 28, 44-49.	3.3	147
5	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematology,the, 2019, 6, e375-e383.	2.2	129
6	Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 2013, 122, 1293-1304.	0.6	125
7	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine, 2018, 24, 450-462.	15.2	123
8	Targeting hedgehog in hematologic malignancy. Blood, 2012, 119, 2196-2204.	0.6	120
9	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111, 2843-2853.	0.6	117
10	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematology,the, 2017, 4, e310-e316.	2.2	97
11	Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate. Clinical Cancer Research, 2006, 12, 626-633.	3.2	86
12	Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 2016, 6, 25476.	1.6	66
13	Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia, 2021, 35, 1229-1242.	3.3	64
14	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 2020, 34, 1775-1786.	3.3	49
15	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 2020, 34, 1613-1625.	3.3	46
16	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	5.8	43
17	How I manage priapism in chronic myeloid leukaemia patients. British Journal of Haematology, 2012, 158, 155-164.	1.2	42
18	Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells and Cloning: Advances and Applications, 2015, 8, 27.	2.3	41

#	Article	IF	Citations
19	Evolving molecular therapy for chronic myeloid leukaemiaâ€”are we on target?. Hematology, 2005, 10, 349-359.	0.7	38
20	Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nature Medicine, 2022, 28, 1439-1446.	15.2	36
21	A â€˜telomere-associated secretory phenotypeâ€™ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia, 2014, 28, 2028-2039.	3.3	35
22	Implementing the EffTox dose-finding design in the Matchpoint trial. BMC Medical Research Methodology, 2017, 17, 112.	1.4	29
23	Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia and Lymphoma, 2012, 53, 2474-2478.	0.6	27
24	ULK1 inhibition promotes oxidative stressâ€“induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 2021, 13, eabd5016.	5.8	26
25	Is There a Role for Dose Modification of TKI Therapy in CML?. Current Hematologic Malignancy Reports, 2019, 14, 337-345.	1.2	25
26	The application of BH3 mimetics in myeloid leukemias. Cell Death and Disease, 2021, 12, 222.	2.7	25
27	Chronic myelogenous leukemia stem cells: Whatâ€™s new?. Current Hematologic Malignancy Reports, 2009, 4, 66-73.	1.2	23
28	Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. Blood, 2014, 124, 4539-4539.	0.6	22
29	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematology,the, 2022, 9, e121-e132.	2.2	21
30	The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochemical Society Transactions, 2014, 42, 809-815.	1.6	18
31	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematology,the, 2022, 9, e262-e275.	2.2	14
32	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood Advances, 2016, 1, 160-169.	2.5	12
33	Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opinion on Drug Discovery, 2017, 12, 465-474.	2.5	12
34	Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death and Disease, 2018, 9, 927.	2.7	12
35	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematology,the, 2022, 9, e276-e288.	2.2	12
36	Targeting Chronic Myeloid Leukemia Stem Cells. Current Hematologic Malignancy Reports, 2013, 8, 14-21.	1.2	11

#	Article	IF	Citations
37	Consensus on <scp>BCR</scp>â€<scp>ABL</scp>1 reporting in chronic myeloid leukaemia in the <scp>UK</scp>. British Journal of Haematology, 2018, 182, 777-788.	1.2	11
38	Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. Cell Death Discovery, 2021, 7, 137.	2.0	10
39	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. Blood, 2018, 132, 457-457.	0.6	10
40	In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors. Bone Marrow Transplantation, 2014, 49, 657-663.	1.3	9
41	CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia. Blood, 2015, 126, 49-49.	0.6	9
42	Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. Scientific Reports, 2016, 6, 24057.	1.6	8
43	Defining niche interactions to target chronic myeloid leukemia stem cells. Haematologica, 2020, 105, 2-4.	1.7	5
44	Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia, 2022, 36, 492-506.	3.3	5
45	Dasatinib for the treatment of chronic phase chronic myeloid leukemia. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	4
46	Exploring Stem Cell Heterogeneity in Chronic Myeloid Leukemia. Trends in Cancer, 2018, 4, 167-169.	3.8	3
47	Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia. Future Oncology, 2009, 5, 455-458.	1.1	2
48	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience. Leukemia Research Reports, 2013, 2, 47-50.	0.2	2
49	Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML). Blood, 2019, 134, 3938-3938.	0.6	2
50	Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia. Blood, 2015, 126, 674-674.	0.6	1
51	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2016, 128, 3057-3057.	0.6	1
52	Developing collaborations to establish a low-cost advanced diagnostic hematology laboratory in Peshawar, Pakistan. Blood Advances, 2017, 1, 36-38.	2.5	0
53	Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. Blood, 2007, 110, 2944-2944.	0.6	0
54	Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy. Blood, 2019, 134, 2935-2935.	0.6	0